This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Dec 2021

Piramal adds antibody CDMO capabilities with investment in Yapan Bio

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

To increase its global CDMO capabilities in the development and manufacturing of large molecules for human clinical trials, Piramal Pharma has invested INR 101.77 crore ($13.47 million) for a 27.78% equity stake in Yapan Bio.

Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/bio-therapeutics, including high containment product classes (up to BSL-2+), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.

Investing in the company is regarded by Piramal as a shrewd move given the speed at which the biologics segment of the pharmaceutical industry is growing.

"During the past decade, biologics and their accompanying development services are the fastest growing segments of the CDMO market," said Peter DeYoung, CEO, Pharma Solutions, Piramal Pharma Limited.

Already, Yapan Bio has earned revenues of INR 11.8 cr ($1.56 million) for H1FY22 and is poised for fast growth in response to strong market demand.

Piramal Pharms Solutions currently offers integrated payload, conjugation and fill/finish services. The biologics capabilities of Yapan Bio can be synergistic with Piramal Pharms Solutions' antibody drug conjugation capabilities, particularly for customers who prefer the speed and simplicity of an integrated programme that involves development, manufacturing, conjugation, and fill/finish.

Mentioned Companies
Piramal Pharma Solutions
View company profile

Related News